Anti-PD-1 treatment for DIO mice in preclinical studies reversed immunosuppression in the tumor microenvironment (TME), with DIO mice exhibiting enhanced efficacy compared to the control group (33). The gene discussed is PDCD1; the disease is neoplasm.